CLINICAL TRIALS PROFILE FOR DEXTROAMPHETAMINE SULFATE
✉ Email this page to a colleague
All Clinical Trials for dextroamphetamine sulfate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000304 ↗ | Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 | Completed | University of Texas | Phase 2 | 1997-08-01 | The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy. |
| NCT00000304 ↗ | Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1997-08-01 | The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy. |
| NCT00000306 ↗ | Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 | Completed | University of Texas | Phase 2 | 1994-09-01 | The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate dependent patients. |
| NCT00000306 ↗ | Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1994-09-01 | The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate dependent patients. |
| NCT01886469 ↗ | A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) | Completed | Ironshore Pharmaceuticals and Development, Inc | Phase 1/Phase 2 | 2013-07-01 | The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD. |
| NCT02884544 ↗ | A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD | Completed | Ironshore Pharmaceuticals and Development, Inc | Phase 2 | 2016-08-01 | The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design. |
| NCT02952196 ↗ | Cannabioids as a New Intervention for Amphetamine Dependence | Withdrawn | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | 2016-11-01 | Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dextroamphetamine sulfate
Condition Name
Clinical Trial Locations for dextroamphetamine sulfate
Trials by Country
Clinical Trial Progress for dextroamphetamine sulfate
Clinical Trial Phase
Clinical Trial Sponsors for dextroamphetamine sulfate
Sponsor Name
